Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04735978 · ClinicalTrials.gov registry record · Phase 1
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
A Phase 1 study of Advanced Solid Tumor, sponsored by Replimune.
- Active
- Registry status
- Phase 1
- Development phase
- 123
- Enrollment target
- 13
- Study locations
NCT04735978: Active Phase 1 study of Advanced Solid Tumor, sponsored by Replimune.
NCT04735978 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by Replimune. The registered enrollment target is 123 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (36% lower). The trial reports 13 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04735978, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by Replimune.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 123 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP3 in adult participants with advanced solid tumors, to evaluate the safety and tolerability of RP3 both as a single agent and in combination with anti-PD1 therapy and to determine the recommended Phase 2 dose (RP2D) of RP3.
Primary Outcome
Percentage of participants with DLTs
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL RP3
Study Locations (13)
Other
- Laboratoire de Recherche Translationnelle en Immunotherapie (LRTI), Gustave Roussy - Villejuif
- University of Athens - Athens
- University General Hospital Attikon - Athens
- Vall d'Hebron Hospital Hospital Universitario Vall d´Hebron (Vall d'Hebron University Hospital) - Barcelona
- Hospital Clinic Barcelona - Barcelona
- START Madrid CIO Clara Campal, Hospital Universitario HM Sanchinarro Unidad de Ensayos Fase I Panta 3 - Madrid
- Hospital Clinico Universitario de Valencia - Valencia
- The Royal Marsden NHS Foundation Trust - London
- Churchill Hospital - Oxford
Iowa
- University of Iowa - Iowa City
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Texas
- MD Anderson Cancer Center - Houston
Merseyside
- The Clatterbridge Cancer Centre NHS Foundation Trust - Bebington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2020-12-29 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 1 |
What the registry record for NCT04735978 still lists
NCT04735978 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT04735978 lists 13 locations in 5 states (Other, Iowa, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT04735978 about?
NCT04735978 is a clinical study titled "Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours". This is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP3 in adult participants with advanced solid tumors, to evaluate the safety and tolerability of RP3 both as a single agent and in combination with anti-PD1 therapy and to determine the recomm...
What is the current status of trial NCT04735978?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 123 participants. The study started on 2020-12-29. Estimated completion is 2026-11-30.
What conditions does trial NCT04735978 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT04735978?
The interventions under investigation include: Nivolumab (BIOLOGICAL), RP3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04735978?
This trial is sponsored by Replimune, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04735978 being conducted?
This trial has 13 study locations across Iowa, Pennsylvania, Texas, Merseyside. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04735978's enrollment target sits among peer trials
123 103rd of 189 higher than 87 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI